Example: Heart Attack

Search clinical trials for: 4'-N-benzoylstaurosporine

Total 50 results

NCT01920204

Unknown status

Midostaurin in Indolent Systemic Mastocytosis

Conditions: Indolent Systemic Mastocytosis
NCT01830361

Completed

Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML

Conditions: Acute Myeloid Leukemia
NCT03512197

Active, not recruiting

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia (AML)
NCT03280030

Active, not recruiting

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Conditions: Acute Myeloid Leukemia
NCT03951961

Recruiting

Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Conditions: Acute Myeloid Leukemia, Adult
NCT04027309

Recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
NCT00866281

Terminated

A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia
NCT00233454

Completed

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Conditions: Systemic Mastocytosis, Aggressive (ASM); Leukemia, Mast Cell; Hematological Non-mast Cell Lineage Disease (AHNMD)
NCT02624570

No longer available

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Conditions: Acute Myeloid Leukemia (AML) With; FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
NCT02723435

Withdrawn

Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

Conditions: Acute Myeloid Leukemia With Gene Mutations; Adult Acute Myeloid Leukemia in Remission
NCT01202877

Completed

PKC412 and 5-Azacytidine

Conditions: Leukemia
NCT04097470

Recruiting

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Conditions: AML/MDS
NCT01429337

Completed

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Conditions: Hepatic Impairment
NCT01883362

Completed

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

Conditions: Acute Myeloid Leukemia
NCT01130662

Completed

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03686345

Recruiting

Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia

Conditions: Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
NCT04496999

Recruiting

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

Conditions: AML, Adult
NCT03207334

Withdrawn

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Conditions: Acute Myeloid Leukemia
NCT00782067

Completed

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Conditions: Leukemia
NCT01846624

Terminated

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults; AML (Adult) With 11q23 (MLL) Abnormalities; AML (Adult) With Del (5q); AML (Adult) With Inv (16) (p13; q22); AML (Adult) With t (16;16) (p13; q22); AML (Adult) With t (8; 21) (q22; q22); Secondary AML (Adult); Untreated AML (Adult)
NCT03379727

Active, not recruiting

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia.

Conditions: Acute Myeloid Leukemia
NCT00093600

Completed

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia (AML)
NCT00045942

Completed

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes
NCT03114228

No longer available

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Conditions: FLT3-mutated Acute Myeloid Leukemia
NCT01282502

Completed

Midostaurin (PKC412) for Locally Advanced Rectal Cancer

Conditions: Adenocarcinoma of the Rectum